MX2016002580A - Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas. - Google Patents
Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas.Info
- Publication number
- MX2016002580A MX2016002580A MX2016002580A MX2016002580A MX2016002580A MX 2016002580 A MX2016002580 A MX 2016002580A MX 2016002580 A MX2016002580 A MX 2016002580A MX 2016002580 A MX2016002580 A MX 2016002580A MX 2016002580 A MX2016002580 A MX 2016002580A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitor
- combination
- treatment
- proliferative diseases
- cell proliferative
- Prior art date
Links
- 229940122531 Anaplastic lymphoma kinase inhibitor Drugs 0.000 title abstract 2
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 title abstract 2
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000002062 proliferating effect Effects 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361871275P | 2013-08-28 | 2013-08-28 | |
| PCT/US2014/053244 WO2015031666A1 (en) | 2013-08-28 | 2014-08-28 | Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016002580A true MX2016002580A (es) | 2016-10-26 |
Family
ID=51541330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016002580A MX2016002580A (es) | 2013-08-28 | 2014-08-28 | Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20160361314A1 (enExample) |
| EP (1) | EP3038652B1 (enExample) |
| JP (1) | JP6479812B2 (enExample) |
| KR (1) | KR20160047521A (enExample) |
| CN (1) | CN106029099A (enExample) |
| AU (3) | AU2014312261A1 (enExample) |
| BR (1) | BR112016004358A8 (enExample) |
| CA (1) | CA2922684A1 (enExample) |
| ES (1) | ES2674361T3 (enExample) |
| MX (1) | MX2016002580A (enExample) |
| RU (1) | RU2016110874A (enExample) |
| WO (1) | WO2015031666A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016167511A2 (ko) * | 2015-04-14 | 2016-10-20 | 한국화학연구원 | N2-(2-메톡시페닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
| KR101772134B1 (ko) | 2015-04-14 | 2017-08-29 | 한국화학연구원 | N2-(2-메톡시페닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
| US11208630B2 (en) * | 2015-12-24 | 2021-12-28 | University Of Florida Research Foundation, Incorporated | AAV production using suspension adapted cells |
| US11395821B2 (en) | 2017-01-30 | 2022-07-26 | G1 Therapeutics, Inc. | Treatment of EGFR-driven cancer with fewer side effects |
| WO2019136451A1 (en) | 2018-01-08 | 2019-07-11 | G1 Therapeutics, Inc. | G1t38 superior dosage regimes |
| CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| ES3055186T3 (en) * | 2019-04-04 | 2026-02-10 | Dana Farber Cancer Inst Inc | Bifunctional compounds comprising a cdk2/5 ligand, a linker and a e3 ubiquitin ligase binding degron for the treatment of cancer |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| JP7642556B2 (ja) | 2019-11-18 | 2025-03-10 | 中外製薬株式会社 | 併用医薬 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| TW202146017A (zh) | 2020-03-05 | 2021-12-16 | 美商輝瑞股份有限公司 | 間變性淋巴瘤激酶抑制劑及周期蛋白依賴型激酶抑制劑之組合 |
| US20230381176A1 (en) * | 2020-09-25 | 2023-11-30 | Ascentage Pharma (Suzhou) Co., Ltd. | A pharmaceutical composition and use thereof for treatment of cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5208123B2 (ja) * | 2006-12-08 | 2013-06-12 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
| EA019941B1 (ru) * | 2006-12-08 | 2014-07-30 | АйАрЭм ЭлЭлСи | Соединения и композиции в качестве ингибиторов протеинкиназы |
| AU2009284098B2 (en) * | 2008-08-22 | 2012-03-29 | Astex Therapeutics Ltd. | Pyrrolopyrimidine compounds as CDK inhibitors |
| EP3025724B1 (en) * | 2009-05-13 | 2018-07-11 | The University of North Carolina At Chapel Hill | Cyclin dependent kinase inhibitors and methods of use |
| US20130035336A1 (en) * | 2010-04-13 | 2013-02-07 | Novartis Ag | Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor for treating cancer |
| PT2670401E (pt) * | 2011-02-02 | 2015-10-12 | Novartis Ag | Métodos de utilização de inibidores de alk |
-
2014
- 2014-08-28 US US14/913,828 patent/US20160361314A1/en not_active Abandoned
- 2014-08-28 WO PCT/US2014/053244 patent/WO2015031666A1/en not_active Ceased
- 2014-08-28 CA CA2922684A patent/CA2922684A1/en not_active Abandoned
- 2014-08-28 EP EP14766301.7A patent/EP3038652B1/en active Active
- 2014-08-28 AU AU2014312261A patent/AU2014312261A1/en not_active Abandoned
- 2014-08-28 CN CN201480059490.0A patent/CN106029099A/zh active Pending
- 2014-08-28 RU RU2016110874A patent/RU2016110874A/ru not_active Application Discontinuation
- 2014-08-28 ES ES14766301.7T patent/ES2674361T3/es active Active
- 2014-08-28 BR BR112016004358A patent/BR112016004358A8/pt not_active IP Right Cessation
- 2014-08-28 MX MX2016002580A patent/MX2016002580A/es unknown
- 2014-08-28 JP JP2016537859A patent/JP6479812B2/ja not_active Expired - Fee Related
- 2014-08-28 KR KR1020167007656A patent/KR20160047521A/ko not_active Withdrawn
-
2017
- 2017-08-25 AU AU2017219093A patent/AU2017219093A1/en not_active Abandoned
-
2018
- 2018-07-16 US US16/035,774 patent/US20180318305A1/en not_active Abandoned
- 2018-09-27 AU AU2018236813A patent/AU2018236813A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017219093A1 (en) | 2017-09-14 |
| AU2014312261A1 (en) | 2016-03-10 |
| US20180318305A1 (en) | 2018-11-08 |
| RU2016110874A3 (enExample) | 2018-06-27 |
| EP3038652B1 (en) | 2018-03-21 |
| JP2016529285A (ja) | 2016-09-23 |
| BR112016004358A8 (pt) | 2020-02-11 |
| WO2015031666A1 (en) | 2015-03-05 |
| AU2018236813A1 (en) | 2018-10-18 |
| RU2016110874A (ru) | 2017-10-04 |
| CA2922684A1 (en) | 2015-03-05 |
| JP6479812B2 (ja) | 2019-03-06 |
| ES2674361T3 (es) | 2018-06-29 |
| CN106029099A (zh) | 2016-10-12 |
| US20160361314A1 (en) | 2016-12-15 |
| KR20160047521A (ko) | 2016-05-02 |
| EP3038652A1 (en) | 2016-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018502251A1 (en) | Formulations of an lsd1 inhibitor | |
| PH12016502355B1 (en) | Pharmaceutical composition | |
| MY192088A (en) | Combinantion therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| MX378263B (es) | Terapia de combinación para el tratamiento del cáncer. | |
| HK1211475A1 (en) | Combination therapy | |
| ZA201606320B (en) | Human plasma kallikrein inhibitors | |
| IN2015DN01156A (enExample) | ||
| MX2015017964A (es) | Inhibidores de bromodominio. | |
| TW201613919A (en) | Inhibitors of Bruton's tyrosine kinase | |
| IN2013MU03583A (enExample) | ||
| MX368903B (es) | Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas. | |
| EA032271B9 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний | |
| PH12016502353A1 (en) | Pharmaceutical composition | |
| IN2014MN02236A (enExample) | ||
| ZA201607489B (en) | Combination comprising a glucocorticoid and edo-s101 | |
| BR112016004358A8 (pt) | combinação farmacêutica de um inibidor de alk e um inibidor de cdk para tratamento de doenças proliferativas de célula, composição farmacêutica, seus usos, e kit | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| MX2018005004A (es) | Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos. | |
| MX373272B (es) | Terapia de combinacion. | |
| EP4385563A3 (en) | Dosage forms and therapeutic uses l-4-chlorokynurenine | |
| MX2015013755A (es) | Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis. | |
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| MX2015007945A (es) | Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas. |